Head Office

Dombivli, India 421201

Get In Touch

info@xtrimoist.com

Clinical Evidence

Psoriasis-Prone Skin

Clinical Study Overview

XTRIMOIST-PS Moisturizing Lotion was evaluated in a clinical study conducted on participants with mild to moderate Psoriasis.

Topical steroid treatment
alone

Topical steroid therapy + XTRIMOIST-PS Moisturizing Lotion

Study Duration

4 Week

Study Design

Monocentric, parallel-group clinical study

Key Clinical Findings

Significant Reduction in Psoriasis Severity

Participants using XTRIMOIST-PS Moisturizing Lotion alongside topical steroid therapy demonstrated significantly greater improvement in psoriasis symptoms compared to steroid therapy alone.

Clinical Results After4 Weeks:

  • 26.8% reduction in PSI score

(PSI = Psoriasis Severity Index, a standard clinical assessment for psoriasis severity.)

Intensive Skin
Hydration

Clinical measurements showed a substantial improvement in skin hydration levels.

Clinical Results 

  • Up to 213% increase in skin hydration within 1 hour
  • 127% increase in hydration after 4 weeks

Hydration levels were measured using MoistureMeter SC, an advanced scientific skin hydration assessment device.

Improved Skin Barrier Function

XTRIMOIST-PS demonstrated significant improvement in skin barrier integrity by reducing Trans Epidermal Water Loss (TEWL).

Clinical Results 

  • 19.3% reduction in TEWL within 1 hour
  • 14.3% reduction in TEWL after 4 weeks

Lower TEWL indicates stronger skin barrier protection and reduced moisture loss.

Clinically Proven Itch Relief

Participants experienced significant improvement in itching associated with psoriasis.

Clinical Results 

  • Up to 97.1% reduction in itching scores after 4 weeks
  • Significantly greater itch relief compared to steroid therapy alone

Participant Satisfaction After 4 Weeks of use:

Agreed scaling
had reduced
0 %
Agreed skin felt
more hydrated
0 %
Agreed itching
had reduced
0 %
Liked the
product overall
0 %

Safety & Tolerance

XTRIMOIST-PS Moisturizing Lotion was found to be well tolerated 
throughout the study.

Clinical Safety Findings:

  • No adverse events reported
  • No irritation, burning, tingling, or pricking sensations observed
  • Excellent skin compatibility throughout 4 weeks of use

Quality of Life Improvement

  • Skin comfort
  • Daily activities
  • Social confidence
  • Work and lifestyle comfort

After 4 weeks:

  • No participants reported severe skin discomfort 
  • No participants reported psoriasis significantly affecting work or social life 

Clinical assessments showed meaningful improvement in daily quality of life for participants using XTRIMOIST-PS.

Conclusion

  • 26.8% Psoriasis Severity
  • 127% increase in hydration 
  • 14.3% reduction after 4 weeks
  • Up to 97.1% reduction in itching
  • Scaling reduction & Increase in overall skin comfort

Clinical evaluation demonstrated that XTRIMOIST-PS Moisturizing Lotion, when used alongside topical steroid therapy, provided significant improvement in compared to topical steroid theraph alone.

At Xtrimoist®, we go beyond surface hydration with barrier-focused skincare engineered to restore, strengthen, and protect sensitive and compromised skin from modern environmental stressors.

Company

Other Links

Products

All Rights Reserved © 2026 Xtrimoist | Developed By Brandvertising Arena

  • Privacy Policy
Scroll to Top